Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUCE-06: ADC + Immunotherapy vs Immunotherapy + Chemotherapy in VHR NMIBC
NCT07879469Phase 2Not yet recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Oct 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in Non-muscle-invasive bladder cancer (NMIBC), sponsored by The Second Hospital of Tianjin Medical University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07879469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07879469.